Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the activity of single agent trastuzumab or lapatinib in patients
not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A
companion biological study will assess factors correlated with sensitivity or resistance to
either one of the compounds